CONKO-011/AIO-SUP-0115/ass.: Rivaroxaban Compared to Low Molecular Weight Heparin in Cancer Patients with Acute Venous Thromboembolism
Oral treatment with rivaroxaban led to an improvement in patient-reported treatment satisfaction, particularly in reducing anticoagulation-related burden, resulting in less patient-requested treatment stops. .
Authors
- Anke Schlenska‐Lange
- Uwe Pelzer (ORCID: https://orcid.org/0000-0001-9213-2737)
- Sabine Semrau (ORCID: https://orcid.org/0000-0001-7049-6003)
- Daniel C. Christoph (ORCID: https://orcid.org/0000-0002-3151-6427)
- A. Lohneis
- Klaus‐Dieter Wernecke (ORCID: https://orcid.org/0000-0002-3653-5520)
- Ralf Ulrich Trappe (ORCID: https://orcid.org/0000-0001-7565-7160)
- Thomas J. Ettrich (ORCID: https://orcid.org/0000-0002-7654-2442)
- Christoph Roderburg (ORCID: https://orcid.org/0000-0002-2245-6362)
- Marianne Sinn (ORCID: https://orcid.org/0000-0002-7155-1278)
- Matthias Hellmann
- Jana Kaethe Striefler
- Thomas Südhoff
- Jürgen Heinz
- Hanno Riess
- Omar Mohamed
- Anett Krziwanie
Institutions
- Universität Hamburg (DE)
- Friedrich-Alexander-Universität Erlangen-Nürnberg (DE)
- University Medical Center Freiburg (DE)
- Düsseldorf University Hospital (DE)
- Integrated Oncology (United States) (US)
- Zimmer Biomet (Germany) (DE)
- University Medical Center Hamburg-Eppendorf (DE)
- Krankenhaus Barmherzige Brüder (DE)
- Praxis für Hämatologie und Onkologie (DE)
- Evangelisches Diakoniekrankenhaus (DE)
- Kliniken Essen-Mitte (DE)
- Klinikum Passau (DE)
- DIAKO (DE)
- University Hospital Cologne (DE)
- Nippon Medical School Hospital (JP)
- University Hospital Ulm (DE)
- Heinrich Heine University Düsseldorf (DE)
- Charité - Universitätsmedizin Berlin (DE)
Publication Details
- Journal
- Oncology Research and Treatment
- Published
- 2025-05-26
- DOI
- https://doi.org/10.1159/000545976
- Citations
- 1
- Primary Topic
- Venous Thromboembolism Diagnosis and Management
- Type
- article
- Field-Weighted Citation Impact
- 1.87
Funders
- Les Laboratories Pierre Fabre
- Bundesinstitut für Arzneimittel und Medizinprodukte
- Bayer Vital